Literature DB >> 26497529

The role of Fc receptors in HIV prevention and therapy.

Austin W Boesch1, Eric P Brown1, Margaret E Ackerman1,2,3.   

Abstract

Over the past decade, a wealth of experimental evidence has accumulated supporting the importance of Fc receptor (FcR) ligation in antibody-mediated pathology and protection in many disease states. Here we present the diverse evidence base that has accumulated as to the importance of antibody effector functions in the setting of HIV prevention and therapy, including clinical correlates, genetic associations, viral evasion strategies, and a rapidly growing number of compelling animal model experiments. Collectively, this work identifies antibody interactions with FcR as important to both therapeutic and prophylactic strategies involving both passive and active immunity. These findings mirror those in other fields as investigators continue to work toward identifying the right antibodies and the right effectors to be present at the right sites at the right time.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Fc receptor; HIV; IgA; IgG; antibody; effector function

Mesh:

Substances:

Year:  2015        PMID: 26497529      PMCID: PMC4955558          DOI: 10.1111/imr.12339

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  167 in total

Review 1.  Structure and function relationships in IgA.

Authors:  J M Woof; M W Russell
Journal:  Mucosal Immunol       Date:  2011-09-21       Impact factor: 7.313

2.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Authors:  Anne-Sophie Dugast; Leonidas Stamatatos; Andrew Tonelli; Todd J Suscovich; Anna F Licht; Iliyana Mikell; Margaret E Ackerman; Hendrik Streeck; P J Klasse; John P Moore; Galit Alter
Journal:  Eur J Immunol       Date:  2014-08-11       Impact factor: 5.532

4.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

5.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

6.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

7.  Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake.

Authors:  Ayumi Yada; Shin Ebihara; Kimio Matsumura; Shota Endo; Tsutomu Maeda; Akira Nakamura; Kenichi Akiyama; Setsuya Aiba; Toshiyuki Takai
Journal:  Cell Immunol       Date:  2003-09       Impact factor: 4.868

8.  Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.

Authors:  Ewald T J van den Bremer; Frank J Beurskens; Marleen Voorhorst; Patrick J Engelberts; Rob N de Jong; Burt G van der Boom; Erika M Cook; Margaret A Lindorfer; Ronald P Taylor; Patrick Hc van Berkel; Paul Whi Parren
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  Differential binding of IgG and IgA to mucus of the female reproductive tract.

Authors:  Kelly M Fahrbach; Olga Malykhina; Daniel J Stieh; Thomas J Hope
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

10.  The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Authors:  Sandeep Gupta; Johannes S Gach; Juan C Becerra; Tran B Phan; Jeffrey Pudney; Zina Moldoveanu; Sarah B Joseph; Gary Landucci; Medalyn Jude Supnet; Li-Hua Ping; Davide Corti; Brian Moldt; Zdenek Hel; Antonio Lanzavecchia; Ruth M Ruprecht; Dennis R Burton; Jiri Mestecky; Deborah J Anderson; Donald N Forthal
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

View more
  21 in total

Review 1.  Systems serology for evaluation of HIV vaccine trials.

Authors:  Margaret E Ackerman; Dan H Barouch; Galit Alter
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

2.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Authors:  Ching-Lan Lu; Dariusz K Murakowski; Stylianos Bournazos; Till Schoofs; Debolina Sarkar; Ariel Halper-Stromberg; Joshua A Horwitz; Lilian Nogueira; Jovana Golijanin; Anna Gazumyan; Jeffrey V Ravetch; Marina Caskey; Arup K Chakraborty; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

3.  Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.

Authors:  Yanqin Ren; Maria Korom; Rebecca M Lynch; R Brad Jones; Ronald Truong; Dora Chan; Szu-Han Huang; Colin C Kovacs; Erika Benko; Jeffrey T Safrit; John Lee; Hermes Garbán; Richard Apps; Harris Goldstein
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 4.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

5.  Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.

Authors:  Shuying S Li; Peter B Gilbert; Lindsay N Carpp; Chul-Woo Pyo; Holly Janes; Youyi Fong; Xiaoying Shen; Scott D Neidich; Derrick Goodman; Allan deCamp; Kristen W Cohen; Guido Ferrari; Scott M Hammer; Magdalena E Sobieszczyk; Mark J Mulligan; Susan P Buchbinder; Michael C Keefer; Edwin DeJesus; Richard M Novak; Ian Frank; M Juliana McElrath; Georgia D Tomaras; Daniel E Geraghty; Xinxia Peng
Journal:  J Virol       Date:  2019-10-15       Impact factor: 6.549

6.  A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants.

Authors:  Allison S Thomas; Melissa Ghulam-Smith; Alex Olson; Carolyn Coote; Oscar Gonzales; Manish Sagar
Journal:  J Immunol Methods       Date:  2020-03-02       Impact factor: 2.287

Review 7.  Non-Neutralizing Antibodies Directed against HIV and Their Functions.

Authors:  Luzia M Mayr; Bin Su; Christiane Moog
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

8.  eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients.

Authors:  Meredith E Davis-Gardner; Matthew R Gardner; Barnett Alfant; Michael Farzan
Journal:  PLoS Pathog       Date:  2017-12-18       Impact factor: 6.823

9.  Conserved HIV Epitopes for an Effective HIV Vaccine.

Authors:  Bikash Sahay; Cuong Q Nguyen; Janet K Yamamoto
Journal:  J Clin Cell Immunol       Date:  2017-08-30

Review 10.  Cell-targeting antibodies in immunity to Ebola.

Authors:  Alan Schmaljohn; George K Lewis
Journal:  Pathog Dis       Date:  2016-03-21       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.